Hybridoma technology

Cell Line Development Services Global Market Report 2022-2030: Increasing Trend of Biologics Outsourcing and Increasing Approval and Demand for Biologics and Biosimilars - ResearchAndMarkets.com

Retrieved on:

Tuesday, January 10, 2023

The "Cell Line Development Services Global Market - Forecast To 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Cell Line Development Services Global Market - Forecast To 2030" report has been added to ResearchAndMarkets.com's offering.
Increasing trend of biologics outsourcing and increasing approval and demand for biologics and biosimilars are driving the market.
Cell line development service global market is classified based on the expression system, cell line type, application and geography.
Based on expression system, cell line development service global market is segmented into microbial, mammalian and others.

Insights on the Biotherapeutics Cell Line Development Global Market to 2027 - Increasing Demand for Monoclonal Antibodies is Driving Growth - ResearchAndMarkets.com

Retrieved on:

Tuesday, September 27, 2022

The report presents a detailed Ansoff matrix analysis for the Global Biotherapeutics Cell Line Development Market.

Key Points:

The report presents a detailed Ansoff matrix analysis for the Global Biotherapeutics Cell Line Development Market.
The Global Biotherapeutics Cell Line Development Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
The report offers a comprehensive evaluation of the Global Biotherapeutics Cell Line Development Market.
The Global Biotherapeutics Cell Line Development Market is segmented based on Type, Source, Product, Application, and Geography.

Identification of an internalizing cancer target for novel antibody drug conjugate by A&G Pharmaceutical and Precision Antibody researchers.

Retrieved on:

Monday, June 7, 2021

Medical specialties, Immunology, Clinical medicine, Medicine, Antibody, Monoclonal antibody, Hybridoma technology, Antigen, Antibody-drug conjugate, Bispecific monoclonal antibody

COLUMBIA, Md., June 7, 2021 /PRNewswire/ --A&G Pharmaceutical ( www.agpharma.com ) and Precision Antibody ( www.precisionantibody.com ) are pleased to announce the publication, in PLOS One, of their collaborative study regarding the identification of Prostaglandin F2 receptor negative regulator as an internalizing cancer cell target and the isolation of proprietary internalizing antibody for antibody drug conjugate development.

Key Points:

COLUMBIA, Md., June 7, 2021 /PRNewswire/ --A&G Pharmaceutical ( www.agpharma.com ) and Precision Antibody ( www.precisionantibody.com ) are pleased to announce the publication, in PLOS One, of their collaborative study regarding the identification of Prostaglandin F2 receptor negative regulator as an internalizing cancer cell target and the isolation of proprietary internalizing antibody for antibody drug conjugate development.
Precision Antibody has developed a customized program to select internalizing antibodies for cell surface targets.
ADCs are composed of a monoclonal antibody binding to a cell surface target, a linker, and a cytotoxic payload.
The approach centered on the identification of targets internalized and expressed on cancer cells by screening hybridoma libraries developed against cancer cell-surface antigens.

Leland Joins Genovac as Vice President of Production & Characterization

Retrieved on:

Tuesday, May 4, 2021

Immunology, Antibody, Hybridoma technology

b'Fargo, North Dakota, May 04, 2021 (GLOBE NEWSWIRE) -- Pete Leland, a 20-year veteran of the biotechnology industry, has joined Genovac Antibody Discovery, Fargo, N.D., as its vice president of production and characterization.\nGenovac is a contract research organization that discovers and develops antibodies for therapeutic, diagnostic and research markets.

Key Points:

b'Fargo, North Dakota, May 04, 2021 (GLOBE NEWSWIRE) -- Pete Leland, a 20-year veteran of the biotechnology industry, has joined Genovac Antibody Discovery, Fargo, N.D., as its vice president of production and characterization.\nGenovac is a contract research organization that discovers and develops antibodies for therapeutic, diagnostic and research markets.
The company\xe2\x80\x99s core technologies \xe2\x80\x93 genetic immunization, advanced hybridoma and single B cell screening \xe2\x80\x93 enable rapid antibody discovery against biopharma\xe2\x80\x99s most challenging targets.\nWith the addition of Leland, Genovac can now provide its clients with robust production and characterization services.\n\xe2\x80\x9cPete is an accomplished and recognized leader in biotechnology,\xe2\x80\x9d said Genovac CEO Brian Walters.
\xe2\x80\x9cGenovac is committed to being a \xe2\x80\x98one-stop shop,\xe2\x80\x99 providing antibody discovery, production and characterization services.
In addition to its headquarters and lab in Fargo, N.D., Genovac operates a second scientific and production facility in Freiburg, Germany.\n'

Abveris Deploys Second Berkeley Lights Beacon® System to Expand Single B Cell Antibody Discovery Capacity

Retrieved on:

Thursday, April 22, 2021

Immunology, Medicine, Branches of biology, Health care, Antibody, Hybridoma technology, Antibody Solutions, GenScript Biotech

b'CANTON, Mass., April 22, 2021 /PRNewswire/ --Abveris, Inc., Boston\'s leader in antibody discovery services, today announced the deployment of a second Berkeley Lights, Inc. Beacon optofluidic system to enable expansion of the Abveris antibody discovery offering.\nThe Abveris Single B Cell Antibody Discovery workflow was first announced in 2019 with the acquisition of the initial Beacon system.

Key Points:

b'CANTON, Mass., April 22, 2021 /PRNewswire/ --Abveris, Inc., Boston\'s leader in antibody discovery services, today announced the deployment of a second Berkeley Lights, Inc. Beacon optofluidic system to enable expansion of the Abveris antibody discovery offering.\nThe Abveris Single B Cell Antibody Discovery workflow was first announced in 2019 with the acquisition of the initial Beacon system.
"Incorporating a second Beacon system will allow us to accelerate this innovation and continue to develop additional techniques for high-content single cell interrogation.
"As they expand capacity with a second Beacon, we look forward to seeing Abveris further become a leader in rapid antibody discovery against a broad range of targets.
Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services.

Abveris Named as One of the Best Places to Work in 2021

Retrieved on:

Thursday, March 11, 2021

Immunology, Branches of biology, Health, Immune system, Antibody, Glycoproteins, Biology, Immunization, Hybridoma technology

CANTON, Mass., March 11, 2021 /PRNewswire/ -- The Business Intelligence Group today announced that it has awarded Abveris a Best Places to Work award.

Key Points:

CANTON, Mass., March 11, 2021 /PRNewswire/ -- The Business Intelligence Group today announced that it has awarded Abveris a Best Places to Work award.
We are honored to be recognized as a Best Places to Work winner, and we have our team to thank for this award."
"Congratulations to Abveris for building an organization focused on employee engagement and performance," said Maria Jimenez, Chief Nominations Officer of Business Intelligence Group.
Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services.

Serum-Free Media Market to Expand More Than Twofold by 2030; COVID-19 Pandemic Hindering Progress in Short Term - Persistence Market Research

Retrieved on:

Wednesday, January 20, 2021

Life sciences, Biology, Branches of biology, Biotechnology, Blood, Cell biology, Alternatives to animal testing, Cell culture, Serum, Hybridoma technology, Biopharmaceutical, Chemically defined medium

Downstream processes are often regarded as a bottleneck of the biopharmaceutical industry, but it is increasing the usage of serum-free media for cell culture growth.

Key Points:

Downstream processes are often regarded as a bottleneck of the biopharmaceutical industry, but it is increasing the usage of serum-free media for cell culture growth.
The CHO cell media segment under media type is expected to hold more than twenty percent of revenue share in the serum-free media market.
Various players in the serum-free media market are focusing on growth strategies such as collaborations and agreement licences.
Persistence Market Research offers a unique perspective and actionable insights on serum-free media in its latest study, presenting historical demand assessment of 2015 2019 and projections for 2020 2030, on the basis of media type (protein expression media, stem cell media, hybridoma media, primary cell media, insect cell media, immunology media, CHO cell media, and chemically-defined media), animal source (camelids and sharks), and end user (biopharmaceutical companies, clinical research organizations, and academic research centers), across seven key regions.

Serum-Free Media Market to Expand More Than Twofold by 2030; COVID-19 Pandemic Hindering Progress in Short Term - Persistence Market Research

Retrieved on:

Wednesday, January 20, 2021

Downstream processes are often regarded as a bottleneck of the biopharmaceutical industry, but it is increasing the usage of serum-free media for cell culture growth.

Key Points:

Downstream processes are often regarded as a bottleneck of the biopharmaceutical industry, but it is increasing the usage of serum-free media for cell culture growth.
The CHO cell media segment under media type is expected to hold more than twenty percent of revenue share in the serum-free media market.
Various players in the serum-free media market are focusing on growth strategies such as collaborations and agreement licences.
Persistence Market Research offers a unique perspective and actionable insights on serum-free media in its latest study, presenting historical demand assessment of 2015 2019 and projections for 2020 2030, on the basis of media type (protein expression media, stem cell media, hybridoma media, primary cell media, insect cell media, immunology media, CHO cell media, and chemically-defined media), animal source (camelids and sharks), and end user (biopharmaceutical companies, clinical research organizations, and academic research centers), across seven key regions.

Kemp Proteins Enter Strategic Partnership for Commercialization of ArtiaBio Technology Platform for Stable Cell Line Development

Retrieved on:

Tuesday, December 8, 2020

Branches of biology, Biology, Immunology, Life sciences, Biotechnology, Cell culture, Cellular senescence, Immortalised cell line, Senescence, Hybridoma technology

Under the Agreements Kemp Proteins will gain access to ArtiaBio proprietary parental cell and vector technology for development of highly productive cell lines and cost effective, rapid manufacturing processes.

Key Points:

Under the Agreements Kemp Proteins will gain access to ArtiaBio proprietary parental cell and vector technology for development of highly productive cell lines and cost effective, rapid manufacturing processes.
The cell lines developed using the ArtiaBio technology will not be royalty bearing and no license fee is applied on success, a distinct delineation between Kemp Proteins and other cell line development companies using their own proprietary technology.
Building out the hybridoma development facility and now the Stable Cell Line Development Service all under our ISO Quality System, demonstrates a continuing successful implementation of our strategy plan," said Michael Keefe, CEO for Kemp Proteins.
Kemp Proteins (formerly Kempbio) is a leading provider of gene-to-protein, hybridoma and cell line development services.

Absolute Antibody Adds SeqPack™ Hybridoma Preservation Kit to Antibody Sequencing Service

Retrieved on:

Tuesday, September 15, 2020

Medical specialties, Immunology, Branches of biology, Biology, Antibody, Monoclonal antibody, Hybridoma technology, Immortalised cell line, Recombinant antibodies

REDCAR, United Kingdom, Sept. 15, 2020 /PRNewswire-PRWeb/ -- Absolute Antibody Ltd. , an industry-leading provider of recombinant antibody products and services, today announced the availability of the SeqPack Hybridoma Preservation Kit, which streamlines the sample submission process for hybridoma sequencing customers worldwide.

Key Points:

REDCAR, United Kingdom, Sept. 15, 2020 /PRNewswire-PRWeb/ -- Absolute Antibody Ltd. , an industry-leading provider of recombinant antibody products and services, today announced the availability of the SeqPack Hybridoma Preservation Kit, which streamlines the sample submission process for hybridoma sequencing customers worldwide.
Absolute Antibody offers hybridoma sequencing services to protect valuable antibodies from mutation or loss, and to enable antibody engineering and recombinant expression.
The SeqPack Hybridoma Preservation Kit is particularly useful for sequencing contaminated hybridoma cell lines, as it preserves any intact cells and prevents the infection from spreading.
In addition to its hybridoma sequencing service, Absolute Antibody offers antibody protein sequencing, antibody engineering, and recombinant expression, as well as a recombinant reagents catalog.